Ansun Biopharma Announces Independent Data Monitoring Committee Recommendation Supporting Continued Phase 3 Development of DAS181 in Immunocompromised Patients with Parainfluenza Infection

Ansun Biopharma has announced a positive development in its ongoing Phase 3 clinical trial evaluating DAS181, an investigational antiviral therapy for parainfluenza pneumonia in immunocompromised patients who require oxygen support.

Following a planned interim review, the trial's independent Data Monitoring Committee (DMC) recommended that the study continue as planned. The committee also noted that the study results currently fall within the "promising zone," a predefined category indicating encouraging efficacy trends while maintaining an acceptable safety profile.

The update offers hope for patients facing a serious respiratory infection that currently has no FDA-approved antiviral treatment.

Why parainfluenza pneumonia is a serious concern

Parainfluenza viruses are common respiratory pathogens that typically cause mild illness in healthy individuals.

However, for people with weakened immune systems, the situation can be very different.

Immunocompromised patients, including those who have undergone organ transplants, received cancer treatment, or are living with conditions that weaken immune function, face a significantly higher risk of severe respiratory complications.

When parainfluenza infection progresses to pneumonia, patients may develop serious breathing difficulties and require supplemental oxygen. In severe cases, the infection can become life-threatening.

Despite the seriousness of the condition, there are currently no FDA-approved antiviral therapies specifically indicated for parainfluenza pneumonia in these vulnerable patients.

What is DAS181?

DAS181, also known as Fludase, is an investigational inhaled antiviral therapy being developed by Ansun Biopharma.

Unlike traditional antiviral drugs that directly target viruses, DAS181 uses a host-directed approach.

The treatment is a recombinant sialidase fusion protein designed to remove sialic acid receptors from the surface of airway epithelial cells.

These receptors are used by influenza and parainfluenza viruses to attach to and infect respiratory cells.

By removing the receptors, DAS181 aims to block viral entry and reduce the spread of infection within the respiratory tract.

This mechanism may offer broad antiviral activity against multiple respiratory viruses that rely on the same cellular entry pathway.

Understanding the Phase 3 study

The ongoing study, known as DAS181-3-01, is a Phase 3 randomized, double-blind, placebo-controlled clinical trial.

The goal of the trial is to evaluate both the safety and effectiveness of DAS181 in immunocompromised patients who have developed parainfluenza pneumonia and require oxygen support.

Because the study is double-blind, neither investigators nor participants know who is receiving DAS181 and who is receiving placebo during the trial.

This design helps ensure unbiased evaluation of treatment outcomes.

What happened during the interim review?

The independent Data Monitoring Committee recently completed its second scheduled review of the study.

The review examined:

• Interim safety data
• Primary efficacy endpoint data
• Overall trial progress

The analysis was conducted after the study reached approximately 75% of the planned information required for the originally designed Cohort 1 population of 72 patients.

Importantly, the study remains blinded, meaning detailed efficacy results have not been publicly disclosed.

After reviewing the available data, the committee recommended:

• Continuing the trial
• Updating the sample size according to predefined statistical procedures
• Maintaining the current study design

The committee also concluded that the observed results met the protocol-defined criteria for being in the "promising zone."

What does the "promising zone" mean?

In adaptive clinical trials, interim analyses are sometimes used to assess whether a study is on track to achieve its objectives.

A "promising zone" designation generally indicates that the treatment is showing positive signals and that increasing the sample size may improve the likelihood of demonstrating statistical significance at the final analysis.

It does not mean the study has already succeeded.

However, it does suggest that the data observed so far are encouraging enough to justify continuing enrollment and collecting additional evidence.

For investors, researchers, and patients, this is typically viewed as a favorable outcome during an interim review.

Why physicians are watching this study closely

Healthcare professionals who care for immunocompromised patients recognize the urgent need for new treatment options.

According to Dr. Rosy Priya Kodiyanplakkal, Assistant Professor of Clinical Medicine at Weill Cornell Medicine and infectious disease specialist at NewYork-Presbyterian/Weill Cornell Medical Center, parainfluenza pneumonia can be severe and life-threatening in patients who require oxygen support.

She noted that there are currently no FDA-approved antiviral therapies specifically indicated for this condition, making the ongoing Phase 3 study particularly important for this vulnerable patient population.

The successful development of DAS181 could potentially fill a significant gap in respiratory infection treatment.

Regulatory support for DAS181

The FDA has already recognized the potential importance of DAS181 through two important regulatory designations.

The investigational therapy has received:

• Fast Track Designation
• Breakthrough Therapy Designation

These programs are designed to support the development of therapies that address serious diseases with unmet medical needs.

The designations may help facilitate regulatory interactions and potentially accelerate the development process if future trial results remain positive.

A different approach to antiviral therapy

One of the unique aspects of DAS181 is its host-directed mechanism.

Many antiviral therapies work by directly targeting viral proteins. While effective, these approaches can sometimes be limited by viral mutations and resistance.

DAS181 instead focuses on modifying the host cell environment to make infection more difficult.

By preventing viruses from attaching to respiratory cells, the treatment aims to stop infection before viruses can enter and replicate.

This strategy may provide broader antiviral activity and reduce the risk of resistance development compared with traditional virus-targeted approaches.

What happens next?

Following the DMC recommendation, the Phase 3 study will continue enrolling and monitoring patients according to the updated statistical plan.

Researchers will collect additional efficacy and safety data before conducting the final analysis.

Because the trial remains blinded, no conclusions can yet be drawn regarding the ultimate success of the study.

However, the positive interim review represents an important milestone and suggests that the program remains on a potentially favorable path.

Final takeaway

Ansun Biopharma's Phase 3 trial of DAS181 has received encouraging support from an independent Data Monitoring Committee following a planned interim analysis.

The committee recommended that the study continue and identified the current results as falling within the protocol-defined "promising zone," indicating positive treatment signals and acceptable safety observations.

For immunocompromised patients with parainfluenza pneumonia, a condition with no approved antiviral treatment options, DAS181 could potentially become an important new therapy if future study results confirm its clinical benefit.

As the trial progresses toward completion, the medical community will be closely watching for final data that could help determine whether DAS181 can address this significant unmet medical need.